# US 2022/0064195 A1 · Synthetic i2 imidazoline receptor ligands for prevention or treatment of human brain disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064195 A1
- Document ID: US20220064195A1
- Status: Published application
- Kind: A1
- Application number: 17/413,738
- Filed: 2018-12-19
- Published: 2022-03-03
- Earliest claimed: 2018-12-19
- Assignees: Universitat De Barcelona; Universidad Del Pais Vasco; Universitat De Les Illes Balears
- Applicants: Universitat de Barcelona; Universidad del País Vasco; Universitat de les Illes Balears
- Inventors: María Carmen ESCOLANO MIRÓN; Mercè PALLÀS LLIBERIA; Cristian Gaspar GRIÑÁN FERRE; Sònia ABÁS PRADES; Luis-Felipe CALLADO HERNANDO; Jesús A. GARCÍA SEVILLA
- Web page: https://patentgrep.com/patent/US20220064195A1

## CPC

- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula I, their respective mirror-image enantiomers, and mixtures—preferably racemic—of both enantiomers, wherein R1 is ethyl or phenyl; R2 is methyl, phenyl, monosubstituted phenyl, benzyl, or monosubstituted benzyl; R3 is selected from the group consisting of: (C1-C6)-alkyl, (C1-C6)-cycloalkyl, —[CH2]n-phenyl, —[CH2]n-1-naphtyl, —[CH2]n-2-naphtyl, and —[CH2]n-[substituted phenyl]; wherein [substituted phenyl] is a phenyl radical with one, two or three substituents independently selected from: F, Cl, Br, (C1-C3)-alkyl, (C1-C3)-alkyloxy, phenyl, phenoxy, —CF3, —OCF3, nitro, —CN, —CO—(C1-C3)-alkyl and benzoyl; and n is an integer between 0 and 4; have a high affinity for imidazoline receptors of the I2 type, i.e. they are I2-IR ligands. Consequently they are applicable in the prevention or treatment of brain disorders in animals, including humans, particularly of neurodegenerative disorders, and more particularly of Alzheimer's disease (AD).

## Claims

### Claim 1

A compound selected from the group consisting of the enantiomer of formula I, its mirror-image enantiomer, and a mixture of both enantiomers, wherein:
R1 is ethyl or phenyl;
R2 is methyl, phenyl, benzyl, monosubstituted phenyl, or monosubstituted benzyl, with a substituent being F, Cl, Br, (C1-C3)-alkyl, or (C1-C3)-alkyloxy; and
R3 is a radical selected from the group consisting of (C1-C6)-alkyl, (C1-C6)-cycloalkyl, —[CH2]n-phenyl, —[CH2]n-1-naphtyl, —[CH2]n-2-naphtyl, and —[CH2]n-[substituted phenyl]; wherein [substituted phenyl] is a phenyl radical with one, two or three substituents which are radicals independently selected from the group consisting of F, Cl, Br, (C1-C3)-alkyl, (C1-C3)-alkyloxy, phenyl, phenoxy, —CF3, —OCF3, nitro, —CN, —CO—(C1-C3)-alkyl, and benzoyl; and n is an integer between 0 and 4.

### Claim 2 (depends on 1)

The compound according to claim 1, which is a mixture of both enantiomers.

### Claim 3 (depends on 2)

The compound according to claim 2, wherein the mixture is a racemic mixture.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein the substituted phenyl is a phenyl radical with one or two substituents.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein n is an integer between 0 and 2.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein R3 is selected from the group consisting of methyl, ethyl, n-propyl, tert-butyl, cyclohexyl, phenyl, 1-naphtyl, 4-methylphenyl, 4-methoxyphenyl, 4-phenoxyphenyl, 3-(trifluoromethyl)phenyl, 4-(trifluoromethyl)phenyl, 4-fluorophenyl, 2-, 3- and 4-chlorophenyl, 4-bromophenyl, 3- and 4-nitrophenyl, 3,4- and 3,5-dichlorophenyl, 3-chloro-4-fluorophenyl, 2-methyl-5-nitrophenyl, (1,1′-biphenyl)-4-yl, benzyl, phenethyl and 4-fluorophenethyl.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein R1 is ethyl.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein R2 is phenyl.

### Claim 9 (depends on 3)

The compound according to claim 3, which is a racemic mixture selected from:
diethyl (1RS,3aSR,6aSR)-5-(3-chloro-4-fluorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-06);
diethyl (1RS,3aRS,6aRS)-1,5-dimethyl-4,6-dioxo-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-25);
diethyl (1RS,3aRS,6aRS)-1-methyl-4,6-dioxo-5-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-31);
diethyl (1RS,3aSR,6aSR)-5-methyl-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-30);
diethyl (1RS,3aSR,6aSR)-5-cyclohexyl-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-07);
diethyl (1RS,3aSR,6aSR)-5-benzyl-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-29);
diethyl (1RS,3aSR,6aSR)-5-(3-nitrophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-28);
diethyl (1RS,3aSR,6aSR)-4,6-dioxo-1,5-diphenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-16);
diethyl (1RS,3aSR,6aSR)-5-(4-methoxyphenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-22);
diphenyl (1RS,3aSR,6aSR)-4,6-dioxo-1,5-diphenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-26);
diethyl (1RS,3aSR,6aSR)-4,6-dioxo-5-phenethyl-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-33);
diethyl (1RS,3aSR,6aSR)-5-(1,1′-biphenyl)-4-yl-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-32);
diethyl (1RS,3aSR,6aSR)-4,6-dioxo-5-(4-phenoxyphenyl)-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-34)
diethyl (1RS,3aSR,6aSR)-5-(4-fluorophenethyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-36)
diethyl (1RS,3aSR,6aSR)-5-(4-fluorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-37)
diethyl (1RS,3aSR,6aSR)-4,6-dioxo-1-phenyl-5-[4-(trifluoromethyl)phenyl]-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-38)
diethyl (1RS,3aSR,6aSR)-5-(3,4-dichlorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-44);
diethyl (1RS,3aSR,6aSR)-4,6-dioxo-1-phenyl-5-(p-tolyl)-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-45);
diethyl (1RS,3aSR,6aSR)-1-benzyl-4,6-dioxo-5-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-46);
diethyl (1RS,3aSR,6aSR)-5-(4-bromophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-47);
diethyl (1RS,3aSR,6aSR)-5-(4-chlorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-49);
diethyl (1RS,3aSR,6aSR)-5-(2-methyl-5-nitrophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-50);
diethyl (1RS,3aSR,6aSR)-4,6-dioxo-1-phenyl-5-propyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-51);
diethyl (1RS,3aSR,6aSR)-4,6-dioxo-1-phenyl-5-[3-(trifluoromethyl)phenyl]-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-52);
diethyl (1RS,3aSR,6aSR)-5-(3-chlorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-53);
diethyl (1RS,3aSR,6aSR)-5-ethyl-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-54);
diethyl (1RS,3aSR,6aSR)-5-(tert-butyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-55);
diethyl (1RS,3aSR,6aSR)-5-(naphth-1-yl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-56);
diethyl (1RS,3aSR,6aSR)-1-benzyl-5-cyclohexyl-4,6-dioxo-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-57);
diethyl (1RS,3aSR,6aSR)-5-(3,5-dichlorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-58);
diethyl (1RS,3aSR,6aSR)-5-(4-nitrophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-59);
diethyl (1RS,3aSR,6aSR)-5-(3-chloro-4-fluorophenyl)-1-(4-fluorophenyl)-4,6-dioxo-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrol-1-phosphonate (I-62);
diethyl (1RS,3aSR,6aSR)-5-(3-chloro-4-fluorophenyl)-1-(4-methoxyphenyl)-4,6-dioxo-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-64);
diethyl (1RS,3aSR,6aSR)-1-(4-fluorophenyl)-4,6-dioxo-5-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-65);
diethyl (1RS,3aSR,6aSR)-1-(4-methoxyphenyl)-4,6-dioxo-5-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-66);
diethyl (1RS,3aSR,6aSR)-5-cyclohexyl-1-(4-fluorophenyl)-4,6-dioxo-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-67);
diethyl (1RS,3aSR,6aSR)-5-cyclohexyl-1-(4-methoxyphenyl)-4,6-dioxo-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-68); and
diethyl (1RS,3aSR,6aSR)-5-(2-chlorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-69).

### Claim 10

Diethyl (1RS,3aSR,6aSR)-5-(3-chloro-4-fluorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate (I-06).

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A method of prevention or treatment of a brain disorder in an animal, including a human, said method comprising administering the compound of claim 1 to said animal.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the brain disorder is a neurodegenerative disorder.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the neurodegenerative disorder is Alzheimer's disease.
